Dr. Nastoupil on Triplet of TGR1202, Ublituximab, and Ibrutinib in CLL
August 10th 2017
Loretta J. Nastoupil, MD, Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses an early-phase trial looking at the triplet regimen of TGR1202, ublituximab, and ibrutinib (Imbruvica) in patients with chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL).